CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TargTex is developing a novel hydrogel treatment for Glioblastoma Multiforme, an aggressive brain tumor. This treatment is designed to be applied after tumor surgery, releasing a molecule that selectively targets residual cancer cells, aiming to improve patient outcomes without the need for additional chemotherapy.
TargTex is a newly founded Portuguese startup with a novel concept to tackle the most lethal type of brain tumor – Glioblastoma Multiforme (GBM).GBM is the most common and aggressive type of primary brain tumor, with a survival rate lower than 5% after 2 years.
The aggressiveness of the disease combined with the lack of effective treatments translates into a terrible prognosis to GBM patients, with a life expectancy of no more than 12 to 18 months after being diagnosed.TargTex team has developed…
TARGTEX SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
